GlassScriptPhysician profile
Kenneth D Phillips
NPI 1053383281
$2,542.79
in general payments reported to CMS, 2019-2025
21 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $106 · 2021: $707 · 2022: $660 · 2023: $586 · 2024: $92.36 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678 · Consulting Fee: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.31 |
| Consulting Fee | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,583.08 | 2021-2023 | |
| Shire North American Group INC | $125.33 | 2019 | |
| Electromed, INC. | $116.53 | 2021-2023 | Smartvest |
| Cardinal Health 110 LLC | $100.00 | 2025 | |
| Pfizer INC. | $77.95 | 2019-2021 | |
| Allergan, INC. | $71.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $64.67 | 2020-2023 | Breztri |
| Lilly USA, LLC | $53.64 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $50.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.70 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $38.14 | 2019-2023 | Spravato |
| Novo Nordisk INC | $31.74 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $30.50 | 2024 | Qelbree |
| Glaxosmithkline, LLC. | $25.88 | 2019 | |
| Amgen INC. | $25.12 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $20.16 | 2024 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $19.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.64 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.49 | 2023 | Jornay Pm |
| Abbott Laboratories | $16.26 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.